首页|重构本草——莪术

重构本草——莪术

扫码查看
通过古籍文献调研、中医药现代研究成果的梳理,结合中医临床及中药学等学科领域内知名专家学者的认识及应用经验,归纳出莪术:功效主要为行气破血,消积止痛.症靶为疼痛.标靶为结节、动脉硬化斑块、肿瘤、脏器纤维化.现代药理研究发现莪术及其有效成分具有抗肿瘤、抗纤维化、抗炎、镇痛、抗血小板聚集、抗血栓形成、抗氧化等作用.莪术具有脾脏、肾脏及生殖发育毒性,且过量服用莪术油后可引起胃肠道刺激症状,大脑皮层兴奋等,故临床中应避免长期大剂量服用,同时注意合理配伍;体虚之人、月经过多及孕妇忌服.临床使用剂量为6~45 g,内服时当根据不同疾病,或同一疾病的不同阶段进行辨证使用,并积极探索莪术用量与症靶、标靶的量效关系构建.
Reconstruction of Chinese materia medica-zedoray rhizome
Through the investigation of ancient books and the sorting of the modern research achievements of traditional Chinese medicine,combined with the understanding and application experience of well-known experts and scholars in desciplinary fields such as traditional Chinese medicine clinical medicine and science of Chinese materia medica,it is concluded that zedoray rhizome mainly has the effects of activating qi-flowing and activating blood circulation,and removing stagnancy and relieving pain. The symptom target is pain. The biochemical indicator targets are nodules,atherosclerotic plaques,tumors,and organ fibrosis. Modern pharmacological studies have found that zedoray rhizome and its active ingredients have the effects of anti-tumor,anti-fibrosis,anti-inflammatory,pain relief,anti-platelet aggregation,anti-thrombosis,and antioxidation. Zedoray rhizome has toxicity to the spleen,kidneys,and reproductive development,and excessive consumption of zedoray rhizome oil can cause gastrointestinal irritaion symptoms,and excitement in the cerebral cortex. Therefore,in clinical practice,taking zedoray rhizome in large doses for a long time should be avoided,and reasonable drug compatibility should be paid attention to. People with body deficiency,excessive menstruation,and pregnant women should avoid taking it. The clinical dosage is 6-45g. When taken orally,it should be used dialectically according to different diseases or different stages of the same disease,and the construction of dose-effect relationship between the dosage of zedoray rhizome and the symptom target and biochemical indicator target should be explored actively.

zedoray rhizomesymptom targetbiochemical indicator targetreconstruction of Chinese materia medicaclinical verification

方心怡、王昭博、孙郡、沈梦菲、田佳星

展开 >

中国中医科学院广安门医院,北京 100053

北京中医药大学,北京 100029

长春中医药大学,长春 130117

莪术 症靶 标靶 重构本草 临床回归

中国中医科学院优秀青年科技人才培养专项中央高水平中医医院临床研究和成果转化能力提升项目临床科研一体化人才专项(续航工程)

ZZ13-YQ-026CZ40907

2024

长春中医药大学学报
长春中医药大学

长春中医药大学学报

CSTPCD
影响因子:0.916
ISSN:1007-4813
年,卷(期):2024.40(5)
  • 9